Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406617 | 0.93 | MDM2 (0.40) | MDM2MDM4TP53CASP3CACNA1B | |
| SCHEMBL29398142 | 0.88 | POLB (0.34) | MDM2PTPN1CASP3 | |
| SCHEMBL30057700 | 0.81 | MDM2 (0.40) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL18429453 | 0.80 | CASP3 (0.47) | MDM2MDM4TP53CASP3 | |
| SCHEMBL29462650 | 0.79 | PTPN1 (0.46) | MDM2PTPN1MDM4TP53CASP3 | |
| SCHEMBL29401351 | 0.79 | POLB (0.43) | PTPN1 | |
| SCHEMBL24579398 | 0.77 | CASP3 (0.46) | MDM2MDM4TP53CASP3 | |
| SCHEMBL29696746 | 0.77 | CASP3 (0.46) | MDM2MDM4TP53CASP3 | |
| SCHEMBL26126637 | 0.77 | CASP3 (0.46) | MDM2MDM4TP53CASP3 | |
| SCHEMBL5491568 | 0.76 | JAK3 (0.44) | MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724215-B1 | PEPTIDOMIMETICS, METHOD OF SYNTHESIS AND USES THEREOF | PASTEUR INSTITUT (FR) | 2022-04-13 | — | — | EP | claimed |
| US-20230288411-A1 | POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT | SYSMEX CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4230643-A1 | POLYPEPTIDE, POLYMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT | SYSMEX CORPORATION (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-116348498-A | Method and kit for determining polypeptide, polymer, solid phase and test substance | 希森美康株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-11472844-B2 | Peptidomimetics, method of synthesis and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-18 | — | — | US | disclosed |
| WO-2022080486-A1 | POLYPEPTIDE, POLYMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT | シスメックス株式会社 | 2022-04-21 | — | — | WO | disclosed |
| EP-3724215-B1 | PEPTIDOMIMETICS, METHOD OF SYNTHESIS AND USES THEREOF | PASTEUR INSTITUT (FR) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230288411-A1 | POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT | BTD, DNPEP, GC | MDM2 1641/4885PTPN1 4519/4885MDM4 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.